Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 459-465

  Kwakernaak, Arjan J ^a   Lambert, Gilles ^b,c   Slagman, Maartje C J ^a   Waanders, Femke ^a   Laverman, Gozewijn D ^d   Petrides, Francine ^b   Dikkeschei, Bert D ^e   Navis, Gerjan ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ DE NANTES   (France)

^d ZGT Hospital   (Netherlands)

^e ISALA HOSPITAL   (Netherlands)

Author keywords

Antiproteinuric treatment; Chronic kidney disease; LDL cholesterol; Non HDL cholesterol; Proprotein convertase subtilisin kexin type 9; Proteinuria

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LIPOPROTEIN; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SODIUM; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; DIET, SODIUM-RESTRICTED; FEMALE; HUMANS; LIPOPROTEINS; LISINOPRIL; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; PROTEINURIA; SERINE ENDOPEPTIDASES; TETRAZOLES; VALINE;

EID: 84872409052     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.11.009     Document Type: Article

References (30)

1. Joven J., Villabona C., Vilella E., Masana L., Alberti R., Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990, 323(9):579-584.
2. Dullaart R.P.F., Gansevoort R.T., Dikkeschei B.D., de Zeeuw D., de Jong P.E., Van Tol A. Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 1993, 44(1):91-97.
3. Krikken J.A., Waanders F., Dallinga-Thie G.M., et al. Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin. Expert Opin Ther Targets 2009, 13(5):497-504.
4. Vogt L., Laverman G.D., Van Tol A., Groen A.K., Navis G., Dullaart R.P.F. Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment. Nephrol Dial Transplant 2006, 21(1):101-106.
5. Kappelle P.J.W.H., Gansevoort R.T., Hillege J.L., Wolffenbuttel B.H., Dullaart R.P.F. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med 2011, 269(2):232-242.
6. Vogt L., Laverman G.D., Dullaart R.P., Navis G. Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction. Nephrol Dial Transplant 2004, 19(1):5-8.
7. Ordonez J.D., Hiatt R.A., Killebrew E.J., Fireman B.H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993, 44(3):638-642.
8. Vaziri N.D., Liang K.H. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996, 50(3):887-893.
9. Warwick G.L., Caslake M.J., Boulton-Jones J.M., Dagen M., Packard C.J., Shepherd J. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990, 39(2):187-192.
10. Warwick G.L., Packard C.J., Demant T., Bedford D.K., Boulton-Jones J.M., Shepherd J. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991, 40(1):129-138.
11. de Sain-van der Velden M.G., Kaysen G.A., Barrett H.A., et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998, 53(4):994-1001.
12. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, (Suppl. 50):S172-S177.
13. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007, 18(3):304-309.
14. Chan D.C., Lambert G., Barrett P.H., Rye K.A., Ooi E.M., Watts G.F. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin Chem 2009, 55(11):2049-2052.
15. Kappelle P.J.W.H., Lambert G., Dahlback B., Nielsen L.B., Dullaart R.P. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. Atherosclerosis 2011, 214(2):492-494.
16. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94(7):2537-2543.
17. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54(6):1038-1045.
18. WHO Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia (accessed May 2012). http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf.
19. Slagman M.C., Waanders F., Hemmelder M.H., et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011, 343:d4366.
20. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
21. Huijgen R., Boekholdt S.M., Arsenault B.J., et al. Plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: a nested case-control study. J Am Coll Cardiol 2012, 59(20):1778-1784.
22. Vogt L., Waanders F., Boomsma F., de Zeeuw D., Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19(5):999-1007.
23. Laverman G.D., Navis G., Henning R.H., de Jong P.E., de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62(3):1020-1025.
24. Costet P., Hoffmann M.M., Cariou B., Guyomarc'h D.B., Konrad T., Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010, 212(1):246-251.
25. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49(2):394-398.
26. Constantinides A., Kappelle P.J.W.H., Lambert G., Dullaart R.P.F. Plasma lipoprotein-associated phospholipase A(2) is inversely correlated with proprotein convertase subtilisin-kexin type 9. Arch Med Res 2012, 43(1):11-14.
27. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353(3):238-248.
28. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
29. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
30. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366(12):1108-1118.